Cargando…

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

Bruton’s tyrosine kinase (BTK) regulates critical signal transduction pathways involved in the pathobiology of rheumatoid arthritis (RA) and other autoimmune disorders. BMS-986142 is a potent and highly selective reversible small molecule inhibitor of BTK currently being investigated in clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillooly, Kathleen M., Pulicicchio, Claudine, Pattoli, Mark A., Cheng, Lihong, Skala, Stacey, Heimrich, Elizabeth M., McIntyre, Kim W., Taylor, Tracy L., Kukral, Daniel W., Dudhgaonkar, Shailesh, Nagar, Jignesh, Banas, Dana, Watterson, Scott H., Tino, Joseph A., Fura, Aberra, Burke, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524405/ https://www.ncbi.nlm.nih.gov/pubmed/28742141 http://dx.doi.org/10.1371/journal.pone.0181782

Ejemplares similares

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants
por: Bihorel, Sébastien, et al.
Publicado: (2020)

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
por: Wu, Chung-Pu, et al.
Publicado: (2021)

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment
por: Heimrich, Konstantin G., et al.
Publicado: (2021)

Data on the effect of Parkinson's disease multimodal complex treatment in a German University Hospital
por: Heimrich, Konstantin G., et al.
Publicado: (2022)

Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2020)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

What Determines That Older Adults Feel Younger Than They Are? Results From a Nationally Representative Study in Germany
por: Heimrich, Konstantin G., et al.
Publicado: (2022)

The impact of loneliness on quality of life in people with Parkinson’s disease: results from the Survey of Health, Ageing and Retirement in Europe
por: Prell, Tino, et al.
Publicado: (2023)

Prophylactic administration of abatacept (CTLA4-Ig; BMS-188667) prevents disease induction and bone destruction in a rat model of collagen-induced arthritis
por: Kliwinski, C, et al.
Publicado: (2005)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Correction: Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2021)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Phase I study of the mitomycin C analogue BMS-181174.
por: Macaulay, V. M., et al.
Publicado: (1998)

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
por: Toyn, Jeremy H., et al.
Publicado: (2014)

A Behaviour Monitoring System (BMS) for Ambient Assisted Living
por: Eisa, Samih, et al.
Publicado: (2017)

The effects of BMS-470539 on lipopolysaccharide-induced acute lung injury
por: Jang, Eun-A, et al.
Publicado: (2019)

Anti-inflammatory activity of edible oyster mushroom is mediated through the inhibition of NF-κB and AP-1 signaling
por: Jedinak, Andrej, et al.
Publicado: (2011)

Heart Rate Variability Analyses in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Heimrich, Konstantin G., et al.
Publicado: (2021)

Prospective associations between hand grip strength and subsequent depressive symptoms in men and women aged 50 years and older: insights from the Survey of Health, Aging, and Retirement in Europe
por: Mendorf, Sarah, et al.
Publicado: (2023)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p27rj2kk262ssu67sarniscfro